SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 25.44+1.5%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (775)9/11/1998 6:37:00 PM
From: Anthony Wong  Read Replies (1) of 1722
 
BBC: Viagra set for European lift-off
Friday, September 11, 1998 Published at 17:12 GMT 18:12 UK

Viagra could go on sale in Europe in about two weeks' time

The top-selling anti-impotence drug Viagra looks certain
to get the go-ahead for immediate sale in the UK and the
rest of the European Union as soon as next week.

Final clearance for the drug requires the signature of the
EU's Industrial Affairs Commissioner, Martin
Bangemann.

But officials in Brussels have signalled that the
Commissioner's approval is a mere formality.

The EU's body of pharmaceutical experts - the EMEA -
cleared the way in August when they voted to approve a
European marketing licence for the revolutionary drug.

Best-selling drug

Viagra has become the fastest-selling new medicine
since its launch in the US in April.

But Viagra's planned launch in Europe was
overshadowed last month when the US Food and Drug
Administration released statistics revealing that there
had been over 100 unconfirmed deaths associated to
Viagra use.

Of the 123 deaths the FDA identified, 69 were confirmed
to have taken place in the US.

Most of the US deaths were linked to heart attacks and
related medical conditions, the FDA said.

Almost three-quarters of the 69 Americans who died had
one or more risk factors for cardiovascular disease,
which contraindicate the use of Viagra.

Warnings

Mr Bangemann's rubber stamp next Tuesday will enable
Viagra's manufacturers, Pfizer, to prepare patient
information labelling in line with EU requirements.

These include clear warnings
about possible effects from
taking the prescription-only
drug.

The EU's Standing
Committee for Proprietary
Medicinal Products (CPMP)
has recommended that
Viagra should not be sold to
women or to males under 18
years of age.

The packaging should warn
against its use by the elderly and those with heart
problems or low blood pressure.

It should also caution against taking other medicines
containing nitrates at the same time.

Viagra users are also likely to be told that if one pill does
not have the expected effect, taking more will not help -
only the potentially painful side-effects will be enhanced.

The EU committee has added an extra proviso - Viagra
users who find the pill's sex-enhancing properties last
more than four hours should consult a doctor.

Two-week countdown

After next Tuesday's expected Commission backing, it
could take Pfizer two weeks to prepare the pills' labelling
before the drug is available in Europe.

"Approval on Tuesday requires just the signature of Mr
Bangemann, then Viagra will be licensed for immediate
sale on prescription subject to the restrictions set by the
pharmaceutical committee," said the Commissioner's
spokesman.

He added: "We are stipulating that Viagra can be
marketed in the EU member states but it is not up to us
to decide how it is paid for - by individuals, by national
health services or whatever.

"That is for each member state to decide."

In the UK, Viagra will cost about half as much as some
doctors feared.

Viagra's manufacturer Pfizer said it planned to charge
the National Health Service œ4.84 per tablet, less than
half the œ10 figure widely quoted in the press.

news.bbc.co.uk
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext